What insurance policy changes affect HCPCS J0013?

There are 8 tracked policy changes affecting HCPCS J0013, including updates from CareSource, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J0013?

Payers that have issued tracked updates for HCPCS J0013 include: CareSource, Aetna, Blue Cross & Blue Shield of Mississippi, Connecticut Medicaid (HUSKY Health), Arkansas Blue Cross Blue Shield, South Dakota Medicaid.

How do I get notified when HCPCS J0013 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J0013. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J0013?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J0013 Insurance Policy Changes

HCPCS J0013 is officially defined as "Esketamine, nasal spray, 1 mg." HCPCS J0013 is referenced in 8 tracked payer policy changes from CareSource, Aetna, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J0013 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
[Ohio] Pharmacy Policy Updates June 2026
CareSource·Effective Sep 1, 2026
CareSource Ohio Medicaid is updating 12 pharmacy policies effective September 1, 2026, including revised policies for specialty medications (ADZYNMA, AFLIBERCEPT, ECULIZUMAB, RITUXIMAB, SPINRAZA, SPRAVATO, UPLIZNA), oncology regimens, medical benefit medications, and one new policy for WASKYRA. Billing teams must review each updated policy for changes to prior authorization requirements, coverage criteria, and billing guidelines before the effective date.
High impact
Esketamine (Spravato) (CPB 0950, reviewed 2026-02-25)
Aetna·Effective Feb 25, 2026
Aetna updated its Esketamine (Spravato) coverage policy (CPB 0950) effective February 25, 2026, establishing new clinical criteria for coverage of this nasal spray for treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation. The policy requires mandatory precertification for all administrations, specifies that treatment must be psychiatrist-prescribed and provider-supervised with 2-hour post-administration monitoring, and limits continuation therapy to 6 months for TRD and 4 weeks for acute suicidal ideation cases. Billing teams must implement prior authorization workflows and ensure proper documentation of clinical criteria at point of service.
High impact
State and School Employees' Health Insurance Plan - Spravato (esketamine)
Blue Cross & Blue Shield of Mississippi·Effective Jan 1, 2026
Effective January 1, 2026, the State and School Employees' Health Insurance Plan (Mississippi) now classifies Spravato (esketamine) as not medically necessary for treatment-resistant depression and major depressive disorder, citing available alternative treatments. All administration and delivery services related to Spravato are also deemed not medically necessary. The drug is considered investigational for all other conditions.
High impact
Hospital Monthly Important Message - 01.19.2026
Connecticut Medicaid (HUSKY Health)·Effective Jan 1, 2026
Connecticut Medicaid has updated multiple fee schedules and billing parameters effective January 1, 2026, including new HCPCS codes, updated DRG weights, new procedure code J0013 for Spravato, and changes to prior authorization requirements for therapy services and radiology.
Medium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·Effective Mar 30, 2026
Arkansas Blue Cross updated three policies effective March 30, 2026: added four new medications (Esketamine, Furosemide, Plozasiran, and Sibeprenlimab) to the self-administered medication list, expanded Beta-thalassemia coverage criteria for Casgevy to include patients receiving ≥10 units packed red blood cells per year, and modified Lyfgenia coverage to allow patients with non-melanoma skin cancer history.
Medium impact
Esketamine Billing Instructions
South Dakota Medicaid·Effective Jan 1, 2026
South Dakota Medicaid is changing the HCPCS code for Esketamine (Spravato) nasal spray billing from S0013 to J0013 effective January 1, 2026. The policy clarifies specific E/M codes and add-on codes for associated professional services and observation time.
Medium impact
Spravato (esketamine)
Blue Cross & Blue Shield of Mississippi·Effective Jan 1, 2026
BCBS Mississippi updated their Spravato (esketamine) policy, maintaining that the drug is not medically necessary for treatment-resistant depression and major depressive disorder due to other available alternatives. The policy also updated the HCPCS code from S0013 to J0013 effective January 1, 2026.
Medium impact
2025.79 - New J Code for Billing Spravato - Spravato Coverage Guidelines
Connecticut Medicaid (HUSKY Health)·Effective Jan 1, 2026
Connecticut Medicaid (HUSKY) is implementing a new J-code (J0013) for billing Spravato (esketamine nasal spray) effective January 1, 2026, replacing the previous S0013 code. The policy updates prior authorization requirements and clarifies billing procedures for both physician offices and outpatient hospitals administering this treatment for depression.

All billing codes J3590 99213 99212 99202 99214 99203

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

[Ohio] Pharmacy Policy Updates June 2026

Esketamine (Spravato) (CPB 0950, reviewed 2026-02-25)

State and School Employees' Health Insurance Plan - Spravato (esketamine)

Hospital Monthly Important Message - 01.19.2026

Policy Criteria Change

Esketamine Billing Instructions

Spravato (esketamine)

2025.79 - New J Code for Billing Spravato - Spravato Coverage Guidelines